Drug intelligence / Profile preview

Eccogene Amylin program

Development stage: Preclinical
Lead developer: Eccogene
Modality: Small Molecules
Administration: Oral

Overview

Eccogene's Amylin Program is a preclinical-stage drug development effort focused on creating a small-molecule agonist of the amylin receptor (AmylinR). Amylin is a peptide hormone co-secreted with insulin that plays a crucial role in glucose homeostasis and satiety by slowing gastric emptying and suppressing glucagon secretion. While current amylin-based therapies are typically injectable peptides, Eccogene's approach utilizes a small-molecule modality, which is intended to provide an oral therapeutic option for the treatment of metabolic diseases, including obesity and type 2 diabetes. As of early 2024, the program remains in the preclinical phase.

Other names: Amylin ProgramEccogene Amylin receptor agonist

Targets

AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on Eccogene Amylin program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eccogene Amylin program.

Explore the full profile